ESMO26

Oncology

Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.

Patients

Claire Gillis reflects on a surprising controversy at ESMO 2026, and the uncomfortable questions it raises for healthcare.

Oncology

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

News

There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.

Oncology

Dr Harold Keer, chief medical officer at Taiho Oncology, discusses the Phase 2 REZILIENT2 trial data presented at ESMO26 and the NSCLC setting.

News

AstraZeneca's CLARITY-Gastric01 trial of sone-ve in CLDN18.2-positive gastrointestinal cancers reveals a 53% reduction in the risk of death.